Cargando…

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study

BACKGROUND: Selecting cognitively normal elderly individuals with higher risk of brain amyloid deposition is critical to the success of prevention trials for Alzheimer's disease (AD). METHODS: Based on the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease study data, we built mach...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Kenichiro, Ihara, Ryoko, Suzuki, Kazushi, Niimi, Yoshiki, Toda, Tatsushi, Jimenez‐Maggiora, Gustavo, Langford, Oliver, Donohue, Michael C., Raman, Rema, Aisen, Paul S., Sperling, Reisa A., Iwata, Atsushi, Iwatsubo, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988864/
https://www.ncbi.nlm.nih.gov/pubmed/33778148
http://dx.doi.org/10.1002/trc2.12135
Descripción
Sumario:BACKGROUND: Selecting cognitively normal elderly individuals with higher risk of brain amyloid deposition is critical to the success of prevention trials for Alzheimer's disease (AD). METHODS: Based on the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease study data, we built machine‐learning models and applied them to our ongoing Japanese Trial‐Ready Cohort (J‐TRC) webstudy participants registered within the first 9 months (n = 3081) of launch to predict standard uptake value ratio (SUVr) of amyloid positron emission tomography. RESULTS: Age, family history, online Cognitive Function Instrument and CogState scores were important predictors. In a subgroup of J‐TRC webstudy participants with known amyloid status (n = 37), the predicted SUVr corresponded well with the self‐reported amyloid test results (area under the curve = 0.806 [0.619–0.992]). DISCUSSION: Our algorithms may be usable for automatic prioritization of candidate participants with higher amyloid risks to be preferentially recruited from the J‐TRC webstudy to in‐person study, maximizing efficiency for the identification of preclinical AD participants.